Subset of venous thromboembolism (VTE) in which blood clot forms in one of the larger, deeper veins that run through the muscles.
- M/C cause of lost disability-adjusted life years (DALY) worldwide
- #3 M/C cause of cardiovascular death worldwide
Etiology
Venous thrombosis refers to the formation, from constituents of blood, of an abnormal mass within the vascular system of a living animal. When this process occurs within the deep veins, it is referred to as deep vein thrombosis (DVT).
Virchow’s triad:
A combination of blood stasis, plasma hypercoagulability and endothelial dysfunction is thought to trigger thrombosis, which starts most often in the valve pockets of large veins.

Increased risk of coagulation:
- Non-O blood groups
- Factor V Leiden mutation
- Oral contraceptive (OCP) use
- Hormone replacement therapy (HRT)
- Advanced age
- Surgery, hospitalization and long-haul travel

Classification
Proximal vein thrombosis is of greater importance and is associated with serious chronic diseases such as active cancer, congestive cardiac failure, respiratory insufficiency, or age above 75 years, whereas distal thrombosis is more often associated with risk factors such as recent surgery and immobilization. Fatal PE is far more likely to result from proximal DVT.
- Proximal DVT: Popliteal vein or thigh veins involved
- Distal DVT: Calf veins involved

Presentation
Lower extremity DVT can be symptomatic or asymptomatic. Patients with lower extremity DVT often do not present with erythema, pain, warmth, swelling, or tenderness.
- Lower extremity pain
- Calf tenderness
- Lower extremity swelling

Uncommon presentations of VTE:
Forms of acute massive venous thrombosis with obstruction of venous drainage to the extremity
- Phlegmasia alba dolens “white legs”: Thrombosis involves only major deep venous channels of extremity, sparing collateral veins characterized by edema, pain, and blanching without cyanosis
- Phlegmasia cerulea dolens “milk legs”: Thrombosis extends to collateral veins, resulting in massive fluid sequestration and more significant edema, characterized by above features in addition to cyanosis, which characteristically progresses from distal to proximal areas and bleb/bulla formation.
- Venous gangrene (both phlegmasia cerulea and alba dolens are complicated by venous gangrene)

Complications
Acute complications:
- Pulmonary embolism (PE) (15% cases) (potentially fatal)
- Recurrent DVT (30%)
- Proximal propagation of thrombus (20-30%)

Long-term complications:
- Post-phlebitis/thrombotic syndrome (17-50% cases): Chronic, potentially disabling condition characterized by leg swelling, pain, venous ectasia, and skin induration, established by 1 year after DVT
- Pulmonary hypertension

Diagnosis
Diagnosis of VTE requires testing and exclusion of other pathologies, and typically involves laboratory measures (such as D-dimer) and diagnostic imaging.
Clinical examination:
Most of these features lack specificity; hence clinical evaluation usually implies the need for further evaluation.
- Homan’s test/dorsiflexion sign: Calf pain at dorsiflexion of the foot
- Bancroft’s sign aka. Moses’ sign: Pain is elicited when the calf muscle is compressed forwards against the tibia, but not when the calf muscle is compressed from side to side
- Neuhoff’s sign: Tender fullness of the calf on palpation
- Perthes manoeuvre: Limb is elevated and an elastic bandage is applied firmly from the toes to the upper 1/3 of the thigh to obliterate the superficial veins only. With the bandage applied the patient is asked to walk for 5 minutes.
- If deep system is competent, the blood will go through and back to the heart
- If the deep system is incompetent, the patient will feel pain in the leg
- Linton test (verification of Perthes manoeuvre): Patient is then placed supine, and the leg is then elevated
- If varices distal to the tourniquet fail to drain after a few seconds, again deep venous obstruction must be considered.
Clinical prediction rules:
Takes into account signs, symptoms and risk factors can be accurately applied to categorize patients as having low, moderate or high probability of DVT. Alternatively, the same rule can be used to categorize cases as “DVT likely” or “DVT unlikely.”

D-dimer assay:
D-dimer is a degradation product of cross-linked fibrin that is formed immediately after thrombin-generated fibrin clots are degraded by plasmin. It reflects a global activation of blood coagulation and fibrinolysis. It is the best recognized biomarker for the initial assessment of suspected VTE.
- Enzyme linked immunosorbent assay (ELISA)
- Latex agglutination assay
- Red blood cell whole blood agglutination assay (simpliRED)

Duplex ultrasound (B-mode imaging and Doppler waveform analysis)
GOLD STANDARD investigation in patients stratified as DVT likely.
- Normal vein:
- Spontaneous blood flow, phasic with respiration, and can be augmented by manual pressure
- Mickey mouse sign: Normal anatomy at saphenofemoral junction (SFJ):
- Common femoral artery (CFA)
- Common femoral vein (CFV)
- Great saphenous vein (GSV)
- DVT findings:
- Failure to compress the vein lumen under gentle probe pressure
- Loss of phasic pattern in which flow is defined as continuous
- Response to valsalva or augmentation

Color Doppler imaging:
Pulsed Doppler signal used to produce images
- Complete absence of spectral or color Doppler signals from the vein lumen

Contrast venography
Definitive diagnostic test for DVT, but it is rarely done because noninvasive tests (D-dimer and venous ultrasound) are more appropriate and accurate to perform in acute DVT episodes. It involves cannulation of a pedal vein with injection of a contrast medium, usually noniodinated, eg, Omnipaque. It is highly sensitive especially in identifying the location, extent and attachment of a clot and also highly specific.
- Constant intraluminal filling defect evident in two or more views (cardinal sign)
- Abrupt cutoff of a deep vein

Impedance plethysmography:
Technique is based on measurement of the rate of change in impedance between two electrodes on the calf when a venous occlusion cuff is deflated. It is portable, safe, and noninvasive but its main drawback remains an apparent insensitivity to calf thrombi and small, nonobstructing proximal vein thrombi.
- Free outflow of venous blood produces a rapid change in impedance while delay in outflow, in the presence of a DVT, leads to a more gradual change.

Magnetic resonance imaging (MRI)
High sensitivity in detecting calf and pelvic DVTs, and upper extremity venous thromboses. and the diagnostic test of choice for suspected iliac vein or inferior vena caval thrombosis when computed tomography venography is contraindicated or technically inadequate. There is no risk of ionizing radiation but it is costly, scarce, and reader expertise is required.

Differential diagnosis:
- Ruptured Baker’s cyst
- Ruptured plantaris tendon
- Calf muscle hematoma
- Cellulitis leg
- Superficial thrombophlebitis
Management
Mechanical prophylaxis:
Enhances blood flow in the deep veins of the leg, preventing venous stasis and hence preventing venous thrombosis. It is indicated in high risk of bleeding with anticoagulation prophylaxis. These includes patients with active or recent gastrointestinal bleeding, patients with hemorrhagic stroke, and those with hemostatic defects such as severe thrombocytopenia. It is contraindicated in patients with evidence of leg ischemia due to peripheral vascular disease. There is a theoretical risk of fibrinolysis and clot dislodgement.
- Intermittent pneumatic compression (IPC) device
- Graduated compression stocking (GCS)
- Venous foot pump
Anticoagulant therapy:
mainstay of treatment. VTE is treated with anticoagulants and occasionally with thrombolytics to prevent thrombus extension and to reduce thrombus size. Anticoagulants are also used to reduce recurrence. New therapies with improved safety profiles are needed to prevent and treat venous thrombosis.
- Unfractionated heparin (UFH)
- Low-molecular-weight heparins (LMWH)
- Vitamin K antagonists
- Warfarin: Drug of choice for long-term therapy to prevent clot formation once acute anticoagulation is achieved.
- Newer drugs:
- Sselective indirect factor Xa inhibitor: Fondaparinux
- Selective direct thrombin inhibitor: Dabigatran
- Selective direct factor Xa inhibitors: Rivaroxaban and apixaban

Summary:
